Private company

CEN BIOTECH INC

CEN BIOTECH INC is a pharmaceutical preparations company.¹ It is headquartered in Windsor, Canada.¹

Last updated Oct 21, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersWindsor, Canada¹
Incorporated inCanada (Federal Level)²
Business address300-3295 Quality Way, Windsor, A6 N8T 3R9²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-3036.9%Operating margin³

-3015.6%Net margin³

-$358.7KFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2021

Other costs

Other costs94¢$590.5K
Income tax6¢$36.4K

Out of $626.9K in revenue.³⁴ The company lost money this year.

Financial statements

Revenue⁵³$626.9K in 2021

Operating income⁶⁵⁷⁸⁹³-$19.0M in 2021+1723% since 2015

Net income⁶⁵⁷⁸⁹³-$18.9M in 2021+686% since 2015

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Revenue		$0⁵	$0⁵			$0³	$626.9K³
Research and development			$32.0K⁷	$41.0K⁸	$0⁸	$0³	$0³
Operating expenses							$19.7M³
Operating income	-$1.0M⁶	-$6.6M⁵	-$11.6M⁷	-$4.4M⁸	-$2.6M⁹	-$2.5M³	-$19.0M³
Income before tax							-$18.9M³
Income tax	$0⁶	$0⁶				$0⁴	-$36.4K⁴
Net income	-$2.4M⁶	-$8.2M⁵	-$14.1M⁷	-$7.5M⁸	-$5.7M⁹	$14.2M³	-$18.9M³
Earnings per share					-$0.21⁹	$0.00¹¹	$0.00⁴
Earnings per share (diluted)					-$0.21⁹	$0.00¹¹	$0.00⁴
Shares (weighted, basic)							61.3M shares⁴
Shares (weighted, diluted)							61.3M shares⁴

Total assets⁶⁵⁷⁸⁹³$8.4M in 2021+2% since 2015

Total liabilities⁶⁵⁷⁸⁹³$10.1M in 2021−28% since 2015

Shareholders’ equity⁸⁷⁹³-$1.7M in 2021−71% since 2015

Cash⁵⁷⁸⁹³$193.2K in 2021+6306% since 2015

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Cash	$3.0K⁵	$62.4K⁷	$85.0K⁸	$3.2K⁸	$3.8K⁹	$1.9K³	$193.2K³
Receivables							$193.1K³
Current assets	$3.0K⁶	$62.4K⁶			$3.8K⁹	$19.8K³	$472.2K³
Property, plant and equipment							$97.4K³
Goodwill							$1.3M³
Intangible assets							$5.1M³
Total assets	$8.3M⁶	$8.4M⁵	$9.0M⁷	$7.3M⁸	$7.3M⁹	$6.3M³	$8.4M³
Accounts payable							$440.3K³
Short-term debt							$1.7M³
Current liabilities	$13.5M⁶	$14.7M⁵	$20.0M⁷	$24.4M⁸	$30.9M⁹	$14.7M³	$9.9M³
Total liabilities	$14.1M⁶	$22.5M⁵	$28.0M⁷	$28.6M⁸	$32.8M⁹	$16.3M³	$10.1M³
Retained earnings							-$46.0M³
Shareholders’ equity	-$5.8M⁸	-$14.0M⁷	-$19.0M⁸	-$21.3M⁹	-$25.5M³	-$10.0M³	-$1.7M³
Shares outstanding	7.0M shares¹²	6.9M shares⁵	25.1M shares⁷	25.5M shares⁸	27.0M shares⁹	27.6M shares³	56.0M shares³

Cash from operations⁵⁷⁸⁹³-$335.5K in 2021−52% since 2016

Capital spending³$23.2K in 2021

Free cash flow³-$358.7K in 2021+5% since 2020

Fiscal year	2016	2017	2018	2019	2020	2021
Cash from operations	-$703.8K⁵	-$2.2M⁷	-$1.7M⁸	-$869.4K⁹	-$340.7K³	-$335.5K³
Stock-based compensation						$15.4M³
Capital spending					$0³	$23.2K³
Free cash flow					-$340.7K	-$358.7K
Cash from investing						$9.9K³
Cash from financing						$520.8K³

Compare CEN BIOTECH INC with another company

What it owns

What CEN BIOTECH INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$119.4K³ Dec 31, 2021	$17.7K⁵ Dec 31, 2017	+576.0%
Accumulated depreciation	$22.0K³ Dec 31, 2021	$35.7K⁹ Dec 31, 2019	−38.3%
Property and equipment, net	$97.4K³ Dec 31, 2021	$0³ Dec 31, 2020
Operating-lease assets (leased space)	$138.1K³ Dec 31, 2021	$0³ Dec 31, 2020

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$193.2K³ Dec 31, 2021	$1.9K³ Dec 31, 2020	+10025.7%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$1.3M³ Dec 31, 2021	$0³ Dec 31, 2020
Intangible assets, net (excluding goodwill)	$5.1M³ Dec 31, 2021	$5.0M³ Dec 31, 2020	+2.3%
Finite-lived intangibles, gross	$7.4M³ Dec 31, 2021	$6.8M³ Dec 31, 2020	+8.2%
Accumulated amortization	$2.3M³ Dec 31, 2021	$1.8M³ Dec 31, 2020	+23.9%
Finite-lived intangibles, net	$5.1M³ Dec 31, 2021	$5.0M³ Dec 31, 2020	+2.3%

Leadership

Who has led CEN BIOTECH INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Joseph A. Byrne2021

Chief financial officer

2025

Chief executive officerBahige B. Chaaban Apr 22, 2021 to Jun 3, 2021¹³
Chief executive officerJoseph A. Byrne Apr 22, 2021 to May 28, 2021¹⁴
PresidentJoseph A. Byrne Jun 3, 2021 to Jun 3, 2021¹⁵
Chief financial officerRichard Boswell Apr 22, 2021 to Apr 26, 2021¹⁶
Chief financial officerAlex Tarrabain Apr 26, 2021 to Jun 25, 2021¹⁷

Board members and other officers (17)

SVP of Deals and AcquisitionsRick Leigh Purdy Apr 13, 2022 to Apr 13, 2022¹⁸
Vice PresidentBrian Payne Apr 22, 2021 to Jun 3, 2021¹⁹
Vice President*Ameen Ferris Apr 26, 2021 to Jun 3, 2021²⁰
Senior Executive VPRichard Boswell Apr 28, 2021 to Jun 3, 2021²¹
Chief Technology OfficerLawrence Lehoux Jul 21, 2021 to Jul 21, 2021²²
Board memberAlex Tarrabain Apr 22, 2021 to Jun 25, 2021²³
Board memberAmeen Ferris Apr 22, 2021 to Jun 3, 2021²⁴
Board memberBahige B. Chaaban Apr 22, 2021 to Jun 3, 2021¹³
Board memberBrian Payne Apr 22, 2021 to Jun 3, 2021¹⁹
Board memberDe Lavenu Harold Andre Aubrey Apr 22, 2021 to Jun 4, 2021²⁵
Board memberDonald Strilchuck Apr 22, 2021 to Jun 4, 2021²⁶
Board memberJoseph A. Byrne Apr 22, 2021 to Jun 3, 2021¹⁴
Board memberRichard Boswell Apr 22, 2021 to Jun 3, 2021¹⁶
Board memberUsamakh Saadikh Apr 22, 2021 to Jun 3, 2021²⁷
Board memberJeffery Allen Thomas Apr 30, 2021 to Apr 30, 2021²⁸
Board memberRick Leigh Purdy May 3, 2021 to Apr 13, 2022²⁹
Board memberLawrence Lehoux Jul 21, 2021 to Jul 21, 2021²²

Timeline

Mar 29, 20238-K Entered a material agreement; Ended a material agreement; Executive or director change³⁰
Sep 16, 20228-K Regulation FD disclosure³¹
Sep 7, 20228-K Regulation FD disclosure³²
Aug 31, 20228-K Entered a material agreement; Unregistered sale of shares; Executive or director change³³
Jul 20, 20228-K Entered a material agreement; Ended a material agreement³⁴
May 27, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁵
May 26, 20228-K Entered a material agreement; Regulation FD disclosure³⁶
May 5, 20228-K Change of auditor³⁷
Apr 21, 20228-K Entered a material agreement; Unregistered sale of shares; Executive or director change³⁸
Apr 19, 20228-K Executive or director change³⁹
Dec 8, 20218-K Entered a material agreement; Unregistered sale of shares; Executive or director change⁴⁰
Oct 13, 20218-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares⁴¹
Apr 22, 2021New chief executive Joseph A. Byrne becomes CEO¹⁴
Apr 22, 2021New chief executive Bahige B. Chaaban becomes CEO¹³

Filings

24 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 12 major events, 1 insider forms, 6 other. The latest 20:

Apr 12, 202315-12G EDGAR
Apr 6, 2023NT 10-K EDGAR
Mar 29, 20238-K EDGAR
Nov 14, 202210-Q EDGAR
Sep 16, 20228-K EDGAR
Sep 7, 20228-K EDGAR
Aug 31, 20228-K EDGAR
Aug 22, 202210-Q EDGAR
Aug 15, 2022NT 10-Q EDGAR
Jul 20, 20228-K EDGAR
May 27, 20228-K EDGAR
May 26, 20228-K EDGAR
May 20, 202210-Q EDGAR
May 12, 2022NT 10-Q EDGAR
May 5, 20228-K EDGAR
Apr 21, 20228-K EDGAR
Apr 19, 20228-K EDGAR
Apr 14, 202210-K EDGAR
Apr 13, 20224 EDGAR
Mar 30, 2022NT 10-K EDGAR

The 24 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How CEN BIOTECH INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARCEN BIOTECH INC¹
CIK0001653821
Filer status<br>emerging growth company¹
Incorporated inCanada (Federal Level)¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
Business address300-3295 Quality Way, Windsor, A6 N8T 3R9¹
Phone226-344-0660¹
Shares outstanding64,126,432 as of Nov 7, 2022⁴
Public float$13.0M as of Jun 30, 2021³
On EDGAR sinceSep 23, 2015¹
Filings189 in all: 8-K (48), 10-Q (22), 5 (17), 3 (13), 424B3 (11), NT 10-Q (11), 4 (10), UPLOAD (9)¹
All 27 form types
10-K (7), CORRESP (7), NT 10-K (7), SC 13D (5), 10-12G/A (4), 5/A (3), 10-K/A (2), 8-K/A (2), 10-12B (1), 10-12B/A (1), 10-12G (1), 10-Q/A (1), 15-12G (1), 3/A (1), D (1), EFFECT (1), RW (1), S-1 (1), SC 13D/A (1)
Latest filingsAnnual report (10-K) Apr 14, 2022
Quarterly report (10-Q) Nov 14, 2022
Latest 8-K (8-K) Mar 29, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCEN BIOTECH INC filings on SEC EDGAR
2
SEC EDGARCEN BIOTECH INC filings on SEC EDGAR
3
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2021
4
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2021
5
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2016
6
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2015
7
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2017
8
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2018
9
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2019
10
SEC EDGARCEN BIOTECH INC 10-Q for fiscal 2022
11
SEC EDGARCEN BIOTECH INC 10-Q for fiscal 2022
12
SEC EDGARCEN BIOTECH INC 10-K for fiscal 2015
13
SEC EDGARBahige B. Chaaban, Chief executive officer
14
SEC EDGARJoseph A. Byrne, Chief executive officer
15
SEC EDGARJoseph A. Byrne, President
16
SEC EDGARRichard Boswell, Chief financial officer
17
SEC EDGARAlex Tarrabain, Chief financial officer
18
SEC EDGARRick Leigh Purdy, SVP of Deals and Acquisitions
19
SEC EDGARBrian Payne, Vice President
20
SEC EDGARAmeen Ferris, Vice President*
21
SEC EDGARRichard Boswell, Senior Executive VP
22
SEC EDGARLawrence Lehoux, Chief Technology Officer
23
SEC EDGARAlex Tarrabain, Board member
24
SEC EDGARAmeen Ferris, Board member
25
SEC EDGARDe Lavenu Harold Andre Aubrey, Board member
26
SEC EDGARDonald Strilchuck, Board member
27
SEC EDGARUsamakh Saadikh, Board member
28
SEC EDGARJeffery Allen Thomas, Board member
29
SEC EDGARRick Leigh Purdy, Board member
30
SEC EDGAREntered a material agreement; Ended a material agreement; Executive or director change
31
SEC EDGARRegulation FD disclosure
32
SEC EDGARRegulation FD disclosure
33
SEC EDGAREntered a material agreement; Unregistered sale of shares; Executive or director change
34
SEC EDGAREntered a material agreement; Ended a material agreement
35
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
36
SEC EDGAREntered a material agreement; Regulation FD disclosure
37
SEC EDGARChange of auditor
38
SEC EDGAREntered a material agreement; Unregistered sale of shares; Executive or director change
39
SEC EDGARExecutive or director change
40
SEC EDGAREntered a material agreement; Unregistered sale of shares; Executive or director change
41
SEC EDGAREntered a material agreement; Completed an acquisition or sale; Unregistered sale of shares